Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW19LB)

• Drug Name: PSB-0952 Drug Info
• Synonyms: CHEMBL590956

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 45141593
  TTD Drug ID: DMW19LB

Molecule-Related Drug Atlas

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TJ004309	DMFB54Y	Ovarian cancer	2C73	Phase 2	[2]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
AB680	DMGONUE	Pancreatic cancer	2C10	Phase 1	[5]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
CPI-006	DMJSFTX	Advanced cancer	2A00-2F9Z	Phase 1	[7]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[10]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[10]

Drug(s) Targeting P2Y purinoceptor 6 (P2RY6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GC021109	DMQBEYV	Alzheimer disease	8A20	Phase 1	[11]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[12]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[12]
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[12]
RB 2	DMCEFUW	Discovery agent	N.A.	Investigative	[1]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[12]
MRS2782	DMZSO4R	Discovery agent	N.A.	Investigative	[13]
MRS2578	DMKMPS6	Discovery agent	N.A.	Investigative	[14]
UDP-beta-S	DMMWHAV	Discovery agent	N.A.	Investigative	[15]
Up3U	DMKQWSB	Discovery agent	N.A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[1]
P2Y purinoceptor 6 (P2RY6)	TTNVSKA	P2RY6_HUMAN	Inhibitor	[1]

References

• [1] Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
• [2] ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Agenus.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
• [6] ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
• [8] CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
• [9] Clinical pipeline report, company report or official report of Surface oncology.
• [10] Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
• [13] Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
• [14] Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
• [15] P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.